Pfizer Inc., the world’s biggest drugmaker, said the Securities and Exchange Commission has requested documents about its Cox-2 class of painkillers.
In its quarterly filing submitted to the regulator today, the company didn’t say when the SEC made its request. New York-based Pfizer earlier received a similar request from the U.S. Justice Department.
In April, the drugmaker suspended sales of Bextra, a Cox-2 painkiller in the same class as Merck & Co.’s Vioxx, which was withdrawn Sept. 30 because of an increased risk of heart attack and stroke in users.
The Food and Drug Administration asked Pfizer to include heart risks on the label of arthritis drug Celebrex.
Need Legal Help?
New York City, Long Island, New Jersey, and Florida
Our New York personal injury attorneys are here to help you when you need it the most.